Chemed (CHE) Financials

$580.49 +2.47 (+0.43%)

Closing price 05/20/2025 03:59 PM Eastern

Extended Trading

$581.24 +0.75 (+0.13%)

As of 08:00 AM Eastern

Annual Income Statements for Chemed

This table shows Chemed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	302	273	250	269	319	220	206	98	109	110
Consolidated Net Income / (Loss)	302	273	250	269	319	220	206	98	109	110
Net Income / (Loss) Continuing Operations	302	273	250	269	319	220	206	98	109	110
Total Pre-Tax Income	399	350	330	350	396	262	240	117	177	180
Total Operating Income	366	341	343	343	390	257	244	113	179	184
Total Gross Profit	854	799	765	770	701	617	555	516	461	456
Total Revenue	2,431	2,264	2,135	2,139	2,080	1,939	1,783	1,667	1,577	1,543
Operating Revenue	2,431	2,264	2,135	2,139	2,080	1,939	1,783	1,667	1,577	1,543
Total Cost of Revenue	1,577	1,466	1,370	1,369	1,378	1,321	1,228	1,151	1,115	1,088
Operating Cost of Revenue	1,577	1,466	1,370	1,369	1,378	1,321	1,228	1,151	1,115	1,088
Total Operating Expenses	488	458	422	427	312	360	311	403	283	271
Selling, General & Admin Expense	424	395	359	367	330	306	271	277	248	238
Depreciation Expense	53	51	49	49	47	41	38	35	34	32
Amortization Expense	10	10	10	10	9.99	4.34	0.40	0.14	0.36	1.13
Other Operating Expenses / (Income)	0.45	2.26	3.69	0.99	-75	9.13	1.30	91	-	-
Total Other Income / (Expense), net	33	9.80	-14	7.28	6.31	4.23	-4.03	3.88	-1.70	-4.33
Interest Expense	1.78	3.11	4.58	1.87	2.36	4.54	4.99	4.27	3.72	3.65
Other Income / (Expense), net	35	13	-9.23	9.14	8.67	8.76	0.96	8.15	2.02	-0.69
Income Tax Expense	97	78	80	82	77	42	34	19	68	70
Basic Earnings per Share	$20.10	$18.11	$16.72	$17.14	$20.02	$13.77	$12.80	$6.11	$6.64	$6.54
Weighted Average Basic Shares Outstanding	15.02M	15.05M	14.93M	15.67M	15.96M	15.97M	16.06M	16.06M	16.38M	16.87M
Diluted Earnings per Share	$19.89	$17.93	$16.53	$16.85	$19.48	$13.31	$12.23	$5.86	$6.48	$6.33
Weighted Average Diluted Shares Outstanding	15.19M	15.20M	15.10M	15.94M	16.40M	16.53M	16.80M	16.74M	16.79M	17.42M
Weighted Average Basic & Diluted Shares Outstanding	14.64M	15.12M	14.95M	14.99M	16.03M	16.06M	144.70M	83.20M	16.40M	16.90M
Cash Dividends to Common per Share	$1.80	$1.56	$1.48	$1.40	$1.32	$1.24	$1.16	$1.08	$1.00	$0.92

This table shows Chemed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	72	90	76	71	65	90	75	53	54	62	57
Consolidated Net Income / (Loss)	72	90	76	71	65	90	75	53	54	62	57
Net Income / (Loss) Continuing Operations	72	90	76	71	65	90	75	53	54	62	57
Total Pre-Tax Income	96	120	101	94	84	116	93	70	71	82	76
Total Operating Income	95	114	92	88	72	111	87	70	73	81	81
Total Gross Profit	216	234	210	206	204	228	202	180	189	197	180
Total Revenue	647	640	606	596	589	586	565	554	560	547	526
Operating Revenue	647	640	606	596	589	586	565	554	560	547	526
Total Cost of Revenue	431	406	396	390	385	358	362	374	371	350	347
Operating Cost of Revenue	431	406	396	390	385	358	362	374	371	350	347
Total Operating Expenses	122	120	118	118	132	116	115	110	117	116	99
Selling, General & Admin Expense	106	104	102	102	116	100	100	95	100	97	84
Depreciation Expense	13	13	13	13	13	13	13	13	12	12	12
Amortization Expense	2.57	2.57	2.55	2.55	2.52	2.52	2.52	2.51	2.51	2.51	2.52
Other Operating Expenses / (Income)	0.05	0.16	0.16	0.04	0.09	0.20	0.34	-0.02	1.74	4.22	0.02
Total Other Income / (Expense), net	0.92	6.25	8.87	5.70	12	4.20	6.42	0.84	-1.65	1.07	-4.39
Interest Expense	0.33	0.50	0.43	0.43	0.43	0.34	0.44	0.77	1.55	1.60	1.27
Other Income / (Expense), net	1.25	6.74	9.30	6.13	13	4.54	6.86	1.61	-0.10	2.67	-3.12
Income Tax Expense	24	30	25	23	19	26	18	17	17	20	20
Basic Earnings per Share	$4.91	$6.06	$5.04	$4.70	$4.30	$5.98	$4.97	$3.54	$3.62	$4.17	$3.82
Weighted Average Basic Shares Outstanding	14.62M	15.02M	15.03M	15.10M	15.12M	15.05M	15.08M	15.06M	14.97M	14.93M	14.89M
Diluted Earnings per Share	$4.86	$6.00	$5.00	$4.65	$4.24	$5.91	$4.93	$3.51	$3.58	$4.13	$3.78
Weighted Average Diluted Shares Outstanding	14.76M	15.19M	15.17M	15.25M	15.34M	15.20M	15.20M	15.22M	15.11M	15.10M	15.04M
Weighted Average Basic & Diluted Shares Outstanding	14.63M	14.64M	14.98M	15.05M	15.14M	15.12M	15.06M	15.08M	15.02M	14.95M	14.87M
Cash Dividends to Common per Share	$0.50	-	$0.50	$0.40	$0.40	-	$0.40	$0.38	$0.38	-	$0.38

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-86	190	41	-130	157	1.33	-6.29	-4.19	0.58	0.60
Net Cash From Operating Activities	417	330	310	309	489	301	287	162	135	172
Net Cash From Continuing Operating Activities	417	330	310	309	489	301	287	162	135	172
Net Income / (Loss) Continuing Operations	302	273	250	269	319	220	206	98	109	110
Consolidated Net Income / (Loss)	302	273	250	269	319	220	206	98	109	110
Depreciation Expense	63	61	59	59	57	45	39	36	35	33
Amortization Expense	0.32	0.58	0.34	0.31	0.31	0.31	0.89	1.75	2.37	2.63
Non-Cash Adjustments To Reconcile Net Income	46	43	38	22	31	30	19	38	21	13
Changes in Operating Assets and Liabilities, net	5.77	-46	-37	-41	82	6.21	23	-11	-31	12
Net Cash From Investing Activities	-144	-61	-59	-58	-62	-191	-105	-68	-40	-50
Net Cash From Continuing Investing Activities	-144	-61	-59	-58	-62	-191	-105	-68	-40	-50
Purchase of Property, Plant & Equipment	-50	-57	-57	-59	-59	-53	-53	-64	-40	-44
Acquisitions	-97	-3.99	-3.53	0.00	-3.60	-138	-53	-4.73	-	-6.61
Sale of Property, Plant & Equipment	3.32	0.64	2.33	0.90	1.69	-	-	-	-	-
Other Investing Activities, net	-0.30	-0.43	-0.88	0.01	-0.82	0.27	0.82	1.42	-0.09	0.43
Net Cash From Financing Activities	-359	-80	-209	-381	-271	-109	-188	-99	-95	-121
Net Cash From Continuing Financing Activities	-359	-80	-209	-381	-271	-109	-188	-99	-95	-121
Repayment of Debt	-2.02	-98	-311	-25	-265	-482	-484	-220	-110	-161
Repurchase of Common Equity	-361	-68	-115	-576	-176	-93	-159	-95	-111	-75
Payment of Dividends	-27	-24	-22	-22	-21	-20	-19	-17	-16	-16
Issuance of Debt	0.00	0.49	221	210	175	483	470	213	127	103
Other Financing Activities, net	31	108	17	33	15	1.98	3.33	20	15	28

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-4.47	-60	16	-90	49	91	13	102	-16	66	-1.86
Net Cash From Operating Activities	33	165	91	78	85	109	29	132	60	100	52
Net Cash From Continuing Operating Activities	33	165	91	78	85	109	29	132	60	100	52
Net Income / (Loss) Continuing Operations	72	90	76	71	65	90	75	53	54	62	57
Consolidated Net Income / (Loss)	72	90	76	71	65	90	75	53	54	62	57
Depreciation Expense	16	16	16	16	16	16	15	15	15	15	15
Amortization Expense	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.33	0.10	0.10	0.09
Non-Cash Adjustments To Reconcile Net Income	12	11	9.12	8.00	18	10	8.94	13	11	12	6.13
Changes in Operating Assets and Liabilities, net	-67	48	-10	-17	-14	-7.45	-70	50	-19	11	-26
Net Cash From Investing Activities	-14	-13	-19	-93	-19	-12	-15	-17	-17	-19	-14
Net Cash From Continuing Investing Activities	-14	-13	-19	-93	-19	-12	-15	-17	-17	-19	-14
Purchase of Property, Plant & Equipment	-13	-13	-14	-11	-12	-12	-12	-16	-17	-18	-13
Acquisitions	-0.23	-	-5.10	-85	-7.30	-	-3.69	-0.31	0.00	-1.49	-0.39
Sale of Property, Plant & Equipment	0.11	0.26	0.14	2.83	0.09	0.13	0.15	0.21	0.15	0.29	0.28
Other Investing Activities, net	-0.28	-0.01	-0.02	-0.26	-0.01	-0.03	-0.24	-0.03	-0.14	-0.04	-0.71
Net Cash From Financing Activities	-24	-212	-56	-74	-16	-6.09	-0.26	-14	-60	-14	-40
Net Cash From Continuing Financing Activities	-24	-212	-56	-74	-16	-6.09	-0.26	-14	-60	-14	-40
Repayment of Debt	0.16	-2.02	-	-	0.00	-	-	-21	-76	-8.65	-37
Repurchase of Common Equity	-33	-209	-58	-56	-38	-40	-14	-13	0.00	-13	-24
Payment of Dividends	-7.33	-7.50	-7.49	-6.06	-6.05	-6.06	-6.03	-5.73	-5.69	-5.63	-5.67
Other Financing Activities, net	17	5.98	8.45	-13	29	39	21	26	23	7.31	7.70

This table presents Chemed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,669	1,668	1,442	1,343	1,435	1,268	976	920	880	852
Total Current Assets	395	501	273	230	329	191	160	176	170	151
Cash & Equivalents	178	264	74	33	163	6.16	4.83	11	15	15
Accounts Receivable	171	182	139	137	127	144	120	114	132	106
Inventories, net	8.19	12	10	10	7.10	7.46	5.71	5.33	5.76	6.31
Prepaid Expenses	26	30	30	33	26	23	19	16	13	13
Current Deferred & Refundable Income Taxes	11	13	19	17	6.60	10	11	30	3.71	11
Plant, Property, & Equipment, net	201	204	200	194	188	176	162	143	121	117
Total Noncurrent Assets	1,073	963	970	919	918	902	654	601	589	584
Noncurrent Note & Lease Receivables	127	126	136	125	123	112	-	-	-	-
Goodwill	667	585	581	579	579	577	511	477	472	472
Intangible Assets	92	90	100	108	118	126	68	55	55	55
Employee Benefit Assets	131	106	93	99	89	77	66	62	54	49
Other Noncurrent Operating Assets	56	56	60	8.14	8.76	9.05	9.21	7.13	7.04	7.23
Total Liabilities & Shareholders' Equity	1,669	1,668	1,442	1,343	1,435	1,268	976	920	880	852
Total Liabilities	550	560	643	719	534	542	384	380	356	339
Total Current Liabilities	286	312	297	302	299	262	192	194	172	171
Accounts Payable	44	64	42	73	54	51	50	48	40	44
Accrued Expenses	57	59	59	56	55	50	46	47	48	44
Current Deferred & Payable Income Tax Liabilities	7.59	6.86	0.00	0.04	9.46	0.13	-	-	-	-
Current Employee Benefit Liabilities	92	88	87	96	91	71	63	63	54	53
Other Current Liabilities	85	94	104	78	89	90	32	25	22	23
Total Noncurrent Liabilities	264	248	346	417	235	279	193	186	184	168
Noncurrent Deferred & Payable Income Tax Liabilities	26	30	39	23	21	19	22	17	14	21
Noncurrent Employee Benefit Liabilities	126	104	92	99	88	76	65	62	54	49
Other Noncurrent Operating Liabilities	112	114	123	110	125	95	17	17	16	13
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,119	1,108	799	623	901	727	591	540	524	513
Total Preferred & Common Equity	1,119	1,108	799	623	901	727	591	540	524	513
Total Common Equity	1,119	1,108	799	623	901	727	591	540	524	513
Common Stock	1,522	1,378	1,187	1,081	998	896	810	731	674	637
Retained Earnings	2,722	2,447	2,198	1,970	1,724	1,426	1,226	1,039	958	866
Treasury Stock	-3,127	-2,720	-2,588	-2,430	-1,823	-1,598	-1,446	-1,231	-1,111	-992
Other Equity Adjustments	2.22	2.08	2.25	2.20	2.34	2.31	2.34	2.20	2.51	2.40

This table presents Chemed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,727	1,769	1,735	1,728	1,562	1,505	1,431	1,356
Total Current Assets	502	490	465	540	395	337	262	199
Cash & Equivalents	174	238	223	313	173	160	58	7.78
Accounts Receivable	286	196	185	177	168	120	154	122
Inventories, net	7.79	9.90	11	11	13	12	11	10
Prepaid Expenses	30	31	29	28	30	29	29	31
Current Deferred & Refundable Income Taxes	4.44	14	17	9.79	11	17	11	28
Plant, Property, & Equipment, net	200	201	202	203	205	208	204	194
Total Noncurrent Assets	1,024	1,078	1,068	985	962	960	965	964
Noncurrent Note & Lease Receivables	131	134	132	132	123	127	131	131
Goodwill	667	667	662	592	585	582	581	580
Intangible Assets	90	95	97	88	93	95	97	102
Employee Benefit Assets	128	127	121	118	104	100	97	90
Other Noncurrent Operating Assets	8.48	56	56	56	57	57	58	60
Total Liabilities & Shareholders' Equity	1,727	1,769	1,735	1,728	1,562	1,505	1,431	1,356
Total Liabilities	545	534	528	544	543	553	551	635
Total Current Liabilities	291	265	262	282	297	302	283	298
Accounts Payable	48	45	43	56	57	41	40	77
Accrued Expenses	66	60	60	62	61	57	63	57
Current Deferred & Payable Income Tax Liabilities	38	3.39	0.00	27	5.14	-	11	0.00
Current Employee Benefit Liabilities	60	73	78	50	75	74	50	67
Other Current Liabilities	79	83	80	87	100	130	114	92
Total Noncurrent Liabilities	254	269	266	262	246	251	268	337
Noncurrent Deferred & Payable Income Tax Liabilities	12	28	28	25	30	37	35	34
Noncurrent Employee Benefit Liabilities	127	122	120	118	103	99	97	90
Other Noncurrent Operating Liabilities	115	119	118	120	112	115	119	117
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,182	1,236	1,207	1,183	1,019	952	880	721
Total Preferred & Common Equity	1,182	1,236	1,207	1,183	1,019	952	880	721
Total Common Equity	1,182	1,236	1,207	1,183	1,019	952	880	721
Common Stock	1,576	1,500	1,453	1,436	1,291	1,277	1,223	1,137
Retained Earnings	2,786	2,639	2,571	2,506	2,363	2,294	2,246	2,141
Treasury Stock	-3,183	-2,905	-2,819	-2,761	-2,637	-2,622	-2,592	-2,559
Other Equity Adjustments	2.26	2.21	2.15	2.12	2.05	2.32	2.28	2.31

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.37%	6.06%	-0.20%	2.87%	7.27%	8.75%	6.96%	5.70%	2.17%	5.98%
EBITDA Growth	11.98%	5.37%	-4.32%	-9.60%	46.07%	9.61%	79.33%	-27.19%	-0.96%	5.60%
EBIT Growth	13.51%	5.75%	-5.09%	-11.59%	49.67%	8.81%	101.83%	-32.96%	-1.63%	7.51%
NOPAT Growth	4.60%	1.85%	-1.10%	-16.35%	45.30%	3.52%	120.19%	-13.54%	-2.78%	9.88%
Net Income Growth	10.82%	9.17%	-7.05%	-15.94%	45.26%	7.00%	109.36%	-9.72%	-1.39%	11.03%
EPS Growth	10.93%	8.47%	-1.90%	-13.50%	46.36%	8.83%	108.70%	-9.57%	2.37%	13.64%
Operating Cash Flow Growth	26.40%	6.59%	0.42%	-36.93%	62.42%	4.91%	76.71%	20.02%	-21.05%	55.51%
Free Cash Flow Firm Growth	-25.80%	13.91%	-5.64%	-41.47%	373.29%	-50.15%	99.62%	0.00%	-23.97%	63.23%
Invested Capital Growth	11.46%	2.66%	6.02%	4.99%	-8.87%	19.94%	7.18%	2.09%	4.71%	0.86%
Revenue Q/Q Growth	2.28%	1.76%	0.27%	0.36%	0.53%	3.46%	1.66%	1.52%	0.31%	1.26%
EBITDA Q/Q Growth	1.08%	8.60%	-3.05%	-10.74%	16.87%	7.12%	1.99%	4.01%	1.46%	0.11%
EBIT Q/Q Growth	1.18%	9.93%	-3.65%	-12.33%	19.67%	6.71%	1.97%	5.24%	1.96%	-0.30%
NOPAT Q/Q Growth	-0.37%	10.63%	-5.40%	-11.94%	17.98%	2.65%	2.51%	26.89%	2.43%	-0.14%
Net Income Q/Q Growth	0.09%	11.42%	-4.77%	-12.72%	17.76%	5.39%	-0.11%	29.50%	2.12%	0.12%
EPS Q/Q Growth	0.45%	11.02%	-3.78%	-11.41%	18.06%	5.80%	-0.49%	30.51%	3.18%	0.48%
Operating Cash Flow Q/Q Growth	15.60%	2.60%	13.40%	-7.02%	4.99%	2.40%	42.07%	-17.94%	-27.51%	-0.50%
Free Cash Flow Firm Q/Q Growth	42.12%	16.95%	0.92%	-4.30%	4.08%	69.43%	42.97%	-25.44%	-31.01%	-3.90%
Invested Capital Q/Q Growth	-5.68%	-0.26%	0.93%	3.25%	7.24%	2.16%	7.14%	16.46%	7.11%	0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	35.14%	35.28%	35.84%	35.98%	33.73%	31.85%	31.13%	30.97%	29.26%	29.53%
EBITDA Margin	19.11%	18.32%	18.44%	19.24%	21.89%	16.08%	15.95%	9.51%	13.81%	14.25%
Operating Margin	15.07%	15.04%	16.09%	16.04%	18.74%	13.28%	13.67%	6.78%	11.34%	11.95%
EBIT Margin	16.50%	15.61%	15.66%	16.46%	19.16%	13.73%	13.72%	7.27%	11.46%	11.91%
Profit (Net Income) Margin	12.42%	12.03%	11.69%	12.55%	15.36%	11.34%	11.53%	5.89%	6.90%	7.14%
Tax Burden Percent	75.60%	77.78%	75.72%	76.66%	80.68%	84.07%	85.79%	83.97%	61.42%	61.22%
Interest Burden Percent	99.56%	99.12%	98.63%	99.47%	99.41%	98.30%	97.96%	96.47%	97.94%	98.02%
Effective Tax Rate	24.40%	22.22%	24.28%	23.34%	19.32%	15.93%	14.21%	16.03%	38.58%	38.78%
Return on Invested Capital (ROIC)	31.05%	31.80%	32.56%	34.74%	40.59%	29.12%	32.00%	15.21%	18.19%	19.23%
ROIC Less NNEP Spread (ROIC-NNEP)	19.78%	25.46%	20.64%	-70.80%	27.68%	33.34%	28.04%	18.76%	16.96%	16.70%
Return on Net Nonoperating Assets (RNNOA)	-3.93%	-3.21%	2.55%	0.49%	-1.34%	4.26%	4.32%	3.24%	2.78%	3.63%
Return on Equity (ROE)	27.12%	28.59%	35.11%	35.23%	39.25%	33.37%	36.33%	18.45%	20.97%	22.86%
Cash Return on Invested Capital (CROIC)	20.21%	29.18%	26.71%	29.87%	49.88%	10.98%	25.07%	13.15%	13.59%	18.37%
Operating Return on Assets (OROA)	24.05%	22.73%	24.01%	25.36%	29.47%	23.72%	25.81%	13.46%	20.87%	21.47%
Return on Assets (ROA)	18.10%	17.52%	17.93%	19.34%	23.64%	19.60%	21.69%	10.91%	12.55%	12.88%
Return on Common Equity (ROCE)	27.12%	28.59%	35.11%	35.23%	39.25%	33.37%	36.33%	18.45%	20.97%	22.86%
Return on Equity Simple (ROE_SIMPLE)	26.99%	24.60%	31.25%	43.09%	35.45%	30.27%	34.76%	18.17%	20.75%	21.49%
Net Operating Profit after Tax (NOPAT)	277	265	260	263	314	216	209	95	110	113
NOPAT Margin	11.40%	11.70%	12.18%	12.29%	15.12%	11.16%	11.72%	5.69%	6.96%	7.32%
Net Nonoperating Expense Percent (NNEP)	11.27%	6.34%	11.92%	105.54%	12.91%	-4.23%	3.97%	-3.55%	1.23%	2.53%
Return On Investment Capital (ROIC_SIMPLE)	24.76%	23.91%	29.02%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	64.86%	64.72%	64.16%	64.02%	66.27%	68.15%	68.87%	69.03%	70.74%	70.47%
SG&A Expenses to Revenue	17.45%	17.45%	16.80%	17.14%	15.88%	15.77%	15.21%	16.60%	15.73%	15.41%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.07%	20.24%	19.75%	19.95%	14.99%	18.57%	17.47%	24.19%	17.93%	17.58%
Earnings before Interest and Taxes (EBIT)	401	353	334	352	398	266	245	121	181	184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	465	415	394	412	455	312	284	159	218	220
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.09	7.92	9.44	12.95	9.32	9.54	7.53	7.02	4.83	4.76
Price to Tangible Book Value (P/TBV)	22.03	20.28	64.04	0.00	41.04	302.97	356.06	441.28	0.00	0.00
Price to Revenue (P/Rev)	3.26	3.87	3.53	3.77	4.04	3.57	2.50	2.28	1.61	1.58
Price to Earnings (P/E)	26.26	32.19	30.19	30.06	26.28	31.51	21.67	38.66	23.29	22.14
Dividend Yield	0.34%	0.27%	0.37%	0.27%	0.25%	0.29%	0.42%	0.45%	0.64%	0.64%
Earnings Yield	3.81%	3.11%	3.31%	3.33%	3.81%	3.17%	4.61%	2.59%	4.29%	4.52%
Enterprise Value to Invested Capital (EV/IC)	8.24	10.08	9.20	10.61	11.15	8.65	6.72	6.16	4.25	4.27
Enterprise Value to Revenue (EV/Rev)	3.19	3.76	3.54	3.84	3.96	3.62	2.55	2.33	1.67	1.63
Enterprise Value to EBITDA (EV/EBITDA)	16.69	20.50	19.20	19.98	18.08	22.50	15.96	24.51	12.06	11.45
Enterprise Value to EBIT (EV/EBIT)	19.32	24.07	22.62	23.35	20.67	26.35	18.56	32.07	14.53	13.70
Enterprise Value to NOPAT (EV/NOPAT)	27.98	32.12	29.07	31.27	26.19	32.41	21.72	40.94	23.92	22.30
Enterprise Value to Operating Cash Flow (EV/OCF)	18.57	25.76	24.40	26.65	16.82	23.28	15.81	23.91	19.39	14.69
Enterprise Value to Free Cash Flow (EV/FCFF)	42.98	35.00	35.43	36.37	21.31	85.92	27.72	47.38	32.01	23.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.12	0.30	0.00	0.12	0.15	0.19	0.21	0.18
Long-Term Debt to Equity	0.00	0.00	0.12	0.30	0.00	0.12	0.15	0.17	0.19	0.16
Financial Leverage	-0.20	-0.13	0.12	-0.01	-0.05	0.13	0.15	0.17	0.16	0.22
Leverage Ratio	1.50	1.63	1.96	1.82	1.66	1.70	1.68	1.69	1.67	1.78
Compound Leverage Factor	1.49	1.62	1.93	1.81	1.65	1.67	1.64	1.63	1.64	1.74
Debt to Total Capital	0.00%	0.00%	10.88%	22.89%	0.00%	11.02%	13.11%	15.77%	17.18%	15.10%
Short-Term Debt to Total Capital	0.00%	0.00%	0.56%	0.00%	0.00%	0.00%	0.00%	1.56%	1.38%	1.24%
Long-Term Debt to Total Capital	0.00%	0.00%	10.32%	22.89%	0.00%	11.02%	13.11%	14.22%	15.80%	13.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	89.12%	77.11%	100.00%	88.98%	86.89%	84.23%	82.82%	84.91%
Debt to EBITDA	0.00	0.00	0.25	0.45	0.00	0.29	0.31	0.64	0.50	0.42
Net Debt to EBITDA	0.00	0.00	0.06	0.37	0.00	0.27	0.30	0.57	0.43	0.35
Long-Term Debt to EBITDA	0.00	0.00	0.23	0.45	0.00	0.29	0.31	0.58	0.46	0.38
Debt to NOPAT	0.00	0.00	0.37	0.70	0.00	0.42	0.43	1.07	0.99	0.81
Net Debt to NOPAT	0.00	0.00	0.09	0.58	0.00	0.39	0.40	0.95	0.85	0.68
Long-Term Debt to NOPAT	0.00	0.00	0.36	0.70	0.00	0.42	0.43	0.96	0.91	0.74
Altman Z-Score	13.27	13.64	11.39	11.18	13.51	11.40	11.33	9.80	8.26	8.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.38	1.61	0.92	0.76	1.10	0.73	0.83	0.91	0.99	0.88
Quick Ratio	1.22	1.43	0.72	0.56	0.97	0.57	0.65	0.64	0.86	0.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	180	243	213	226	386	82	164	82	82	108
Operating Cash Flow to CapEx	903.36%	587.57%	563.48%	534.17%	856.33%	568.16%	543.08%	252.71%	340.42%	388.58%
Free Cash Flow to Firm to Interest Expense	101.32	78.20	46.55	121.05	164.03	18.00	32.81	19.20	22.08	29.60
Operating Cash Flow to Interest Expense	234.55	106.27	67.60	165.20	207.77	66.43	57.54	38.04	36.45	47.05
Operating Cash Flow Less CapEx to Interest Expense	208.58	88.19	55.60	134.28	183.50	54.74	46.95	22.99	25.74	34.94
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.46	1.46	1.53	1.54	1.54	1.73	1.88	1.85	1.82	1.80
Accounts Receivable Turnover	13.79	14.11	15.44	16.20	15.37	14.72	15.29	13.57	13.24	13.37
Inventory Turnover	156.16	131.59	134.43	159.20	189.35	200.67	222.42	207.51	184.84	174.27
Fixed Asset Turnover	12.02	11.22	10.85	11.22	11.44	11.48	11.69	12.61	13.21	13.86
Accounts Payable Turnover	29.15	27.67	23.84	21.52	26.17	26.10	24.92	26.16	26.79	24.02
Days Sales Outstanding (DSO)	26.47	25.86	23.65	22.53	23.75	24.79	23.87	26.90	27.58	27.30
Days Inventory Outstanding (DIO)	2.34	2.77	2.72	2.29	1.93	1.82	1.64	1.76	1.97	2.09
Days Payable Outstanding (DPO)	12.52	13.19	15.31	16.96	13.95	13.99	14.65	13.95	13.63	15.19
Cash Conversion Cycle (CCC)	16.29	15.45	11.05	7.86	11.73	12.62	10.86	14.71	15.93	14.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	941	844	822	775	739	810	676	630	618	590
Invested Capital Turnover	2.72	2.72	2.67	2.83	2.69	2.61	2.73	2.67	2.61	2.63
Increase / (Decrease) in Invested Capital	97	22	47	37	-72	135	45	13	28	5.05
Enterprise Value (EV)	7,752	8,508	7,561	8,223	8,232	7,013	4,539	3,886	2,626	2,518
Market Capitalization	7,931	8,772	7,537	8,071	8,395	6,929	4,455	3,796	2,532	2,442
Book Value per Share	$74.69	$73.55	$53.71	$40.49	$56.50	$45.39	$36.93	$33.84	$32.30	$30.41
Tangible Book Value per Share	$24.03	$28.72	$7.91	($4.12)	$12.82	$1.43	$0.78	$0.54	($0.21)	($0.84)
Total Capital	1,119	1,108	896	808	901	817	681	642	633	605
Total Debt	0.00	0.00	98	185	0.00	90	89	101	109	91
Total Long-Term Debt	0.00	0.00	93	185	0.00	90	89	91	100	84
Net Debt	-178	-264	23	152	-163	84	84	90	93	77
Capital Expenditures (CapEx)	46	56	55	58	57	53	53	64	40	44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-69	-75	-94	-105	-132	-78	-37	-19	-8.49	-28
Debt-free Net Working Capital (DFNWC)	109	189	-20	-72	30	-72	-32	-7.48	6.82	-13
Net Working Capital (NWC)	109	189	-25	-72	30	-72	-32	-17	-1.93	-21
Net Nonoperating Expense (NNE)	-25	-7.62	10	-5.58	-5.09	-3.56	3.46	-3.26	1.04	2.65
Net Nonoperating Obligations (NNO)	-178	-264	23	152	-163	84	84	90	93	77
Total Depreciation and Amortization (D&A)	63	61	60	59	57	46	40	37	37	36
Debt-free, Cash-free Net Working Capital to Revenue	-2.85%	-3.32%	-4.39%	-4.91%	-6.37%	-4.01%	-2.06%	-1.12%	-0.54%	-1.80%
Debt-free Net Working Capital to Revenue	4.49%	8.34%	-0.92%	-3.37%	1.46%	-3.69%	-1.79%	-0.45%	0.43%	-0.84%
Net Working Capital to Revenue	4.49%	8.34%	-1.15%	-3.37%	1.46%	-3.69%	-1.79%	-1.05%	-0.12%	-1.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$20.10	$18.11	$16.72	$17.14	$20.02	$13.77	$12.80	$6.11	$6.64	$6.54
Adjusted Weighted Average Basic Shares Outstanding	15.02M	15.05M	14.93M	15.67M	15.96M	15.97M	16.06M	16.06M	16.38M	16.87M
Adjusted Diluted Earnings per Share	$19.89	$17.93	$16.53	$16.85	$19.48	$13.31	$12.23	$5.86	$6.48	$6.33
Adjusted Weighted Average Diluted Shares Outstanding	15.19M	15.20M	15.10M	15.94M	16.40M	16.53M	16.80M	16.74M	16.79M	17.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.64M	15.12M	14.95M	14.99M	16.03M	16.06M	15.97M	16.16M	16.31M	16.99M
Normalized Net Operating Profit after Tax (NOPAT)	277	265	260	263	314	216	209	95	110	113
Normalized NOPAT Margin	11.40%	11.70%	12.18%	12.29%	15.12%	11.16%	11.72%	5.69%	6.96%	7.32%
Pre Tax Income Margin	16.43%	15.47%	15.44%	16.38%	19.04%	13.50%	13.44%	7.01%	11.23%	11.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	225.42	113.73	72.92	188.53	169.15	58.69	49.02	28.37	48.66	50.42
NOPAT to Interest Expense	155.66	85.23	56.74	140.78	133.49	47.71	41.88	22.22	29.55	30.98
EBIT Less CapEx to Interest Expense	199.45	95.64	60.92	157.61	144.89	46.99	38.42	13.32	37.95	38.31
NOPAT Less CapEx to Interest Expense	129.69	67.14	44.74	109.85	109.23	36.02	31.29	7.17	18.85	18.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	8.97%	8.62%	8.82%	8.20%	6.60%	9.00%	9.08%	17.69%	15.12%	14.15%
Augmented Payout Ratio	128.64%	33.47%	54.70%	222.70%	61.56%	51.12%	86.38%	114.09%	117.27%	82.22%

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.79%	9.23%	7.38%	7.60%	5.19%	7.18%	7.23%	4.24%	5.58%	1.05%	-2.26%
EBITDA Growth	11.21%	3.78%	7.39%	27.10%	15.05%	33.28%	18.01%	-15.37%	-12.60%	-11.14%	-16.23%
EBIT Growth	13.06%	4.04%	8.27%	32.54%	16.77%	38.02%	20.54%	-18.27%	-14.96%	-13.09%	-19.02%
NOPAT Growth	27.67%	-1.33%	-0.98%	26.24%	0.52%	41.53%	16.08%	-25.67%	-18.21%	-19.43%	-14.19%
Net Income Growth	10.37%	0.30%	1.09%	32.80%	20.13%	44.95%	31.80%	-19.68%	-15.66%	-16.75%	-21.01%
EPS Growth	14.62%	1.52%	1.42%	32.48%	18.44%	43.10%	30.42%	-20.23%	-15.17%	-13.60%	-16.92%
Operating Cash Flow Growth	-61.27%	51.91%	212.92%	-41.42%	39.77%	8.35%	-44.39%	133.86%	-40.16%	57.62%	-53.96%
Free Cash Flow Firm Growth	-331.72%	-117.09%	-314.93%	-338.42%	248.87%	344.70%	1,232.00%	-8.32%	-208.01%	-62.79%	-143.56%
Invested Capital Growth	15.83%	11.46%	17.87%	24.27%	3.19%	2.66%	3.88%	0.00%	9.72%	6.02%	8.46%
Revenue Q/Q Growth	1.09%	5.58%	1.73%	1.13%	0.57%	3.79%	1.93%	-1.13%	2.47%	3.83%	-0.91%
EBITDA Q/Q Growth	-17.90%	16.46%	6.53%	9.18%	-23.38%	20.51%	26.08%	-1.17%	-11.24%	6.70%	-9.59%
EBIT Q/Q Growth	-20.41%	18.89%	7.64%	11.01%	-26.76%	23.72%	31.77%	-2.20%	-13.43%	8.05%	-10.65%
NOPAT Q/Q Growth	-17.00%	23.87%	3.82%	19.61%	-35.86%	24.33%	32.35%	-4.76%	-9.68%	1.97%	-15.25%
Net Income Q/Q Growth	-20.55%	19.19%	6.90%	9.03%	-27.80%	20.14%	40.43%	-1.37%	-12.89%	9.24%	-14.42%
EPS Q/Q Growth	-19.00%	20.00%	7.53%	9.67%	-28.26%	19.88%	40.46%	-1.96%	-13.32%	9.26%	-14.09%
Operating Cash Flow Q/Q Growth	-80.14%	82.19%	16.77%	-8.32%	-22.12%	275.30%	-78.14%	118.73%	-39.63%	92.63%	-8.06%
Free Cash Flow Firm Q/Q Growth	-500.50%	86.48%	34.67%	-536.79%	-55.71%	70.06%	-27.53%	372.73%	-232.31%	532.89%	-105.87%
Invested Capital Q/Q Growth	7.15%	-5.68%	1.31%	13.13%	3.11%	-0.26%	6.81%	-6.06%	2.57%	0.93%	2.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	33.45%	36.58%	34.64%	34.59%	34.64%	38.84%	35.81%	32.43%	33.82%	36.05%	34.10%
EBITDA Margin	17.33%	21.33%	19.34%	18.47%	17.11%	22.45%	19.34%	15.63%	15.64%	18.06%	17.57%
Operating Margin	14.65%	17.79%	15.20%	14.79%	12.28%	19.01%	15.38%	12.55%	13.00%	14.88%	15.36%
EBIT Margin	14.84%	18.85%	16.74%	15.82%	14.41%	19.79%	16.60%	12.84%	12.98%	15.37%	14.77%
Profit (Net Income) Margin	11.09%	14.11%	12.50%	11.90%	11.03%	15.37%	13.28%	9.64%	9.66%	11.36%	10.80%
Tax Burden Percent	75.00%	75.19%	75.00%	75.55%	76.96%	77.91%	80.37%	75.88%	76.05%	75.40%	74.37%
Interest Burden Percent	99.66%	99.59%	99.58%	99.54%	99.50%	99.71%	99.53%	98.92%	97.87%	98.09%	98.37%
Effective Tax Rate	25.00%	24.81%	25.00%	24.45%	23.04%	22.09%	19.63%	24.12%	23.95%	24.60%	25.63%
Return on Invested Capital (ROIC)	29.12%	36.45%	29.41%	29.38%	25.29%	40.26%	33.14%	26.29%	26.55%	29.98%	31.07%
ROIC Less NNEP Spread (ROIC-NNEP)	28.84%	34.33%	26.18%	27.13%	19.95%	37.54%	20.26%	23.88%	22.69%	30.90%	20.93%
Return on Net Nonoperating Assets (RNNOA)	-5.94%	-6.82%	-4.78%	-4.81%	-3.39%	-4.74%	-0.93%	-0.77%	0.95%	3.81%	0.90%
Return on Equity (ROE)	23.18%	29.64%	24.63%	24.57%	21.91%	35.53%	32.20%	25.52%	27.51%	33.80%	31.97%
Cash Return on Invested Capital (CROIC)	16.47%	20.21%	13.77%	9.74%	27.79%	29.18%	25.03%	28.98%	21.47%	26.71%	27.01%
Operating Return on Assets (OROA)	21.39%	27.47%	23.89%	22.80%	20.93%	28.81%	25.31%	19.93%	20.53%	23.56%	23.51%
Return on Assets (ROA)	15.99%	20.57%	17.84%	17.15%	16.02%	22.38%	20.25%	14.96%	15.28%	17.43%	17.20%
Return on Common Equity (ROCE)	23.18%	29.64%	24.63%	24.57%	21.91%	35.53%	32.20%	25.52%	27.51%	33.80%	31.97%
Return on Equity Simple (ROE_SIMPLE)	26.13%	0.00%	24.42%	24.92%	23.95%	0.00%	24.00%	23.79%	27.22%	0.00%	36.33%
Net Operating Profit after Tax (NOPAT)	71	86	69	67	56	87	70	53	55	61	60
NOPAT Margin	10.99%	13.38%	11.40%	11.17%	9.45%	14.81%	12.36%	9.52%	9.89%	11.22%	11.42%
Net Nonoperating Expense Percent (NNEP)	0.28%	2.12%	3.23%	2.25%	5.34%	2.72%	12.88%	2.41%	3.87%	-0.92%	10.14%
Return On Investment Capital (ROIC_SIMPLE)	6.01%	7.65%	-	-	-	7.83%	-	-	-	6.84%	-
Cost of Revenue to Revenue	66.55%	63.42%	65.36%	65.41%	65.36%	61.16%	64.19%	67.57%	66.18%	63.95%	65.90%
SG&A Expenses to Revenue	16.32%	16.29%	16.82%	17.16%	19.67%	17.14%	17.64%	17.15%	17.87%	17.73%	15.95%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	18.80%	18.79%	19.44%	19.80%	22.36%	19.83%	20.43%	19.88%	20.82%	21.18%	18.74%
Earnings before Interest and Taxes (EBIT)	96	121	101	94	85	116	94	71	73	84	78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	112	137	117	110	101	132	109	87	88	99	93
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.62	7.09	7.32	6.80	8.19	7.92	7.66	8.51	9.09	9.44	8.96
Price to Tangible Book Value (P/TBV)	21.20	22.03	19.08	18.31	19.23	20.28	22.88	29.41	39.73	64.04	163.93
Price to Revenue (P/Rev)	3.62	3.26	3.80	3.51	4.22	3.87	3.51	3.71	3.70	3.53	3.04
Price to Earnings (P/E)	29.17	26.26	29.98	27.27	34.19	32.19	31.94	35.79	33.40	30.19	24.66
Dividend Yield	0.31%	0.34%	0.28%	0.30%	0.25%	0.27%	0.37%	0.35%	0.35%	0.37%	0.34%
Earnings Yield	3.43%	3.81%	3.34%	3.67%	2.93%	3.11%	3.13%	2.79%	2.99%	3.31%	4.06%
Enterprise Value to Invested Capital (EV/IC)	8.76	8.24	8.83	8.11	10.77	10.08	9.03	10.03	9.45	9.20	8.05
Enterprise Value to Revenue (EV/Rev)	3.55	3.19	3.70	3.42	4.09	3.76	3.43	3.63	3.68	3.54	3.08
Enterprise Value to EBITDA (EV/EBITDA)	18.56	16.69	19.16	17.68	21.90	20.50	19.99	21.74	20.90	19.20	16.14
Enterprise Value to EBIT (EV/EBIT)	21.42	19.32	22.21	20.54	25.64	24.07	23.76	26.00	24.78	22.62	18.90
Enterprise Value to NOPAT (EV/NOPAT)	30.21	27.98	31.67	28.64	35.38	32.12	31.90	34.60	32.15	29.07	23.85
Enterprise Value to Operating Cash Flow (EV/OCF)	24.15	18.57	24.38	26.65	26.46	25.76	23.73	23.03	29.58	24.40	23.99
Enterprise Value to Free Cash Flow (EV/FCFF)	57.11	42.98	69.40	92.25	39.37	35.00	36.76	34.61	46.03	35.43	31.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.12	0.14
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.12	0.13
Financial Leverage	-0.21	-0.20	-0.18	-0.18	-0.17	-0.13	-0.05	-0.03	0.04	0.12	0.04
Leverage Ratio	1.46	1.50	1.48	1.50	1.53	1.63	1.68	1.72	1.77	1.96	1.78
Compound Leverage Factor	1.46	1.49	1.47	1.49	1.52	1.63	1.67	1.70	1.73	1.92	1.75
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.36%	10.88%	12.26%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.55%	0.56%	0.61%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.80%	10.32%	11.66%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.64%	89.12%	87.74%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.25	0.25
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.10	0.06	0.23
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.23	0.24
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.37	0.37
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.15	0.09	0.34
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.36	0.35
Altman Z-Score	13.95	12.72	13.94	13.07	14.38	13.17	12.45	12.56	12.57	10.82	9.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.73	1.38	1.85	1.78	1.91	1.61	1.33	1.11	0.93	0.92	0.67
Quick Ratio	1.58	1.22	1.64	1.56	1.74	1.43	1.15	0.93	0.75	0.72	0.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-67	-11	-82	-126	29	65	38	53	-19	15	-3.37
Operating Cash Flow to CapEx	248.66%	1,318.67%	675.46%	941.65%	700.08%	932.27%	251.34%	817.48%	358.49%	557.71%	394.79%
Free Cash Flow to Firm to Interest Expense	-202.63	-22.25	-192.25	-292.92	67.69	189.92	86.02	68.36	-12.46	9.12	-2.65
Operating Cash Flow to Interest Expense	99.53	330.49	211.99	180.69	198.94	317.44	65.15	171.62	39.00	62.59	40.93
Operating Cash Flow Less CapEx to Interest Expense	59.50	305.42	180.60	161.50	170.52	283.39	39.23	150.62	28.12	51.36	30.56
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.44	1.46	1.43	1.44	1.45	1.46	1.53	1.55	1.58	1.53	1.59
Accounts Receivable Turnover	10.75	13.79	13.04	15.30	13.85	14.11	15.36	17.03	15.97	15.44	17.75
Inventory Turnover	175.37	156.16	136.49	133.42	138.48	131.59	126.79	128.81	132.44	134.43	143.84
Fixed Asset Turnover	12.37	12.02	11.70	11.38	11.27	11.22	11.15	10.93	10.92	10.85	11.08
Accounts Payable Turnover	31.23	29.15	30.15	35.58	30.68	27.67	21.80	25.06	26.75	23.84	19.77
Days Sales Outstanding (DSO)	33.96	26.47	27.98	23.85	26.35	25.86	23.76	21.43	22.86	23.65	20.56
Days Inventory Outstanding (DIO)	2.08	2.34	2.67	2.74	2.64	2.77	2.88	2.83	2.76	2.72	2.54
Days Payable Outstanding (DPO)	11.69	12.52	12.11	10.26	11.90	13.19	16.75	14.56	13.65	15.31	18.46
Cash Conversion Cycle (CCC)	24.36	16.29	18.55	16.33	17.09	15.45	9.89	9.70	11.97	11.05	4.64
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,008	941	997	984	870	844	846	792	843	822	814
Invested Capital Turnover	2.65	2.72	2.58	2.63	2.68	2.72	2.68	2.76	2.69	2.67	2.72
Increase / (Decrease) in Invested Capital	138	97	151	192	27	22	32	0.04	75	47	64
Enterprise Value (EV)	8,832	7,752	8,806	7,984	9,375	8,508	7,639	7,945	7,966	7,561	6,556
Market Capitalization	9,006	7,931	9,045	8,207	9,689	8,772	7,812	8,105	8,003	7,537	6,463
Book Value per Share	$80.74	$74.69	$82.11	$79.75	$78.29	$73.55	$67.60	$63.39	$58.87	$53.71	$48.40
Tangible Book Value per Share	$29.03	$24.03	$31.50	$29.60	$33.33	$28.72	$22.65	$18.35	$13.47	$7.91	$2.65
Total Capital	1,182	1,119	1,236	1,207	1,183	1,108	1,019	952	901	896	822
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	21	98	101
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16	93	96
Net Debt	-174	-178	-238	-223	-313	-264	-173	-160	-37	23	93
Capital Expenditures (CapEx)	13	13	13	8.23	12	12	12	16	17	18	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	38	-69	-13	-20	-56	-75	-76	-125	-74	-94	-102
Debt-free Net Working Capital (DFNWC)	212	109	226	203	258	189	97	35	-16	-20	-94
Net Working Capital (NWC)	212	109	226	203	258	189	97	35	-21	-25	-99
Net Nonoperating Expense (NNE)	-0.69	-4.70	-6.65	-4.31	-9.35	-3.27	-5.16	-0.64	1.26	-0.81	3.26
Net Nonoperating Obligations (NNO)	-174	-178	-238	-223	-313	-264	-173	-160	-37	23	93
Total Depreciation and Amortization (D&A)	16	16	16	16	16	16	15	15	15	15	15
Debt-free, Cash-free Net Working Capital to Revenue	1.52%	-2.85%	-0.54%	-0.86%	-2.43%	-3.32%	-3.41%	-5.73%	-3.43%	-4.39%	-4.79%
Debt-free Net Working Capital to Revenue	8.51%	4.49%	9.49%	8.69%	11.23%	8.34%	4.37%	1.59%	-0.75%	-0.92%	-4.43%
Net Working Capital to Revenue	8.51%	4.49%	9.49%	8.69%	11.23%	8.34%	4.37%	1.59%	-0.98%	-1.15%	-4.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.91	$6.06	$5.04	$4.70	$4.30	$5.98	$4.97	$3.54	$3.62	$4.17	$3.82
Adjusted Weighted Average Basic Shares Outstanding	14.62M	15.02M	15.03M	15.10M	15.12M	15.05M	15.08M	15.06M	14.97M	14.93M	14.89M
Adjusted Diluted Earnings per Share	$4.86	$6.00	$5.00	$4.65	$4.24	$5.91	$4.93	$3.51	$3.58	$4.13	$3.78
Adjusted Weighted Average Diluted Shares Outstanding	14.76M	15.19M	15.17M	15.25M	15.34M	15.20M	15.20M	15.22M	15.11M	15.10M	15.04M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	14.63M	14.64M	14.98M	15.05M	15.14M	15.12M	15.06M	15.08M	15.02M	14.95M	14.87M
Normalized Net Operating Profit after Tax (NOPAT)	71	86	69	67	56	87	70	53	55	61	60
Normalized NOPAT Margin	10.99%	13.38%	11.40%	11.17%	9.45%	14.81%	12.36%	9.52%	9.89%	11.22%	11.42%
Pre Tax Income Margin	14.79%	18.77%	16.67%	15.75%	14.34%	19.73%	16.52%	12.70%	12.70%	15.07%	14.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	291.80	241.73	237.60	219.71	199.79	338.99	211.06	92.24	46.88	52.47	61.17
NOPAT to Interest Expense	216.02	171.59	161.88	155.19	130.98	253.75	157.21	68.41	35.71	38.30	47.31
EBIT Less CapEx to Interest Expense	251.78	216.67	206.22	200.52	171.37	304.94	185.14	71.24	36.00	41.25	50.80
NOPAT Less CapEx to Interest Expense	175.99	146.53	130.49	136.01	102.56	219.70	131.29	47.41	24.83	27.08	36.95
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	9.19%	8.97%	8.50%	8.04%	8.42%	8.62%	9.43%	10.03%	9.34%	8.82%	8.37%
Augmented Payout Ratio	124.54%	128.64%	72.13%	57.39%	45.88%	33.47%	26.09%	32.42%	45.54%	54.70%	140.83%

Frequently Asked Questions About Chemed's Financials

When does Chemed's financial year end?

According to the most recent income statement we have on file, Chemed's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Chemed's net income changed over the last 9 years?

Chemed's net income appears to be on an upward trend, with a most recent value of $302.00 million in 2024, rising from $110.27 million in 2015. The previous period was $272.51 million in 2023. See where experts think Chemed is headed by visiting Chemed's forecast page.

What is Chemed's operating income?

Chemed's total operating income in 2024 was $366.49 million, based on the following breakdown:

Total Gross Profit: $854.35 million
Total Operating Expenses: $487.86 million

How has Chemed revenue changed over the last 9 years?

Over the last 9 years, Chemed's total revenue changed from $1.54 billion in 2015 to $2.43 billion in 2024, a change of 57.5%.

How much debt does Chemed have?

Chemed's total liabilities were at $549.58 million at the end of 2024, a 1.9% decrease from 2023, and a 62.1% increase since 2015.

How much cash does Chemed have?

In the past 9 years, Chemed's cash and equivalents has ranged from $4.83 million in 2018 to $263.96 million in 2023, and is currently $178.35 million as of their latest financial filing in 2024.

How has Chemed's book value per share changed over the last 9 years?

Over the last 9 years, Chemed's book value per share changed from 30.41 in 2015 to 74.69 in 2024, a change of 145.6%.

Related Companies

This page (NYSE:CHE) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Financials

Frequently Asked Questions About Chemed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemed (CHE) Financials

Annual Income Statements for Chemed

Quarterly Income Statements for Chemed

Annual Cash Flow Statements for Chemed

Quarterly Cash Flow Statements for Chemed

Annual Balance Sheets for Chemed

Quarterly Balance Sheets for Chemed

Annual Metrics And Ratios for Chemed

Quarterly Metrics And Ratios for Chemed

Frequently Asked Questions About Chemed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools